Remember Me Don't have an account? Register Forgotten password? Reset it
The website of the Clinical Services Journal

Extra ‘triple therapy’ drug for type 2 diabetes

NICE has published final guidance recommending dapagliflozin for treating type 2 diabetes in ‘triple therapy’. Dapagliflozin can be added as a third drug where two drugs for type 2 diabetes are not controlling a person’s blood sugar.

 Professor Carole Longson, director of the NICE centre for health technology evaluation, said: “Having a range of drug options makes it easier to tailor treatments for type 2 diabetes to each person’s individual needs. This new guidance recommends dapagliflozin in triple therapy – only in combination with metformin and a sulfonylurea – which will widen the choice available for people whose diabetes isn’t well controlled with two drugs.”



Other news

Upcoming Events

Crossing Continents, Sharing Knowledge

Queen Elizabeth Hospital Birmingham
1st April 2017

The British Society of Audiology Annual Conference

Majestic Hotel, Harrogate
29th – 30th June 2017

Latest Issue

Clinical Services Journal

Clinical Services Journal

Mar 2017

The evolution of patient warming

Register now to apply for regular copies of Clinical Services Journal and free access to premium content, as well as our regular newsletters.